PODXL, podocalyxin like, 5420

N. diseases: 156; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0005684
Disease: Malignant neoplasm of urinary bladder
Malignant neoplasm of urinary bladder 		0.010 Biomarker disease BEFREE Through restoration assays, we observed that PODXL overexpressing countervailed NNT-AS1 depletion-mediated suppression on BC cell growth and Wnt pathway. 31782983 2020
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.010 Biomarker disease BEFREE Through restoration assays, we observed that PODXL overexpressing countervailed NNT-AS1 depletion-mediated suppression on BC cell growth and Wnt pathway. 31782983 2020
CUI: C0025202
Disease: melanoma
melanoma 		0.010 AlteredExpression disease BEFREE PODXL and DEL-1 expression in melanoma patients were associated with poor survival and thus can be used as prognostic markers. 31622599 2020
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder 		0.010 Biomarker disease BEFREE Through restoration assays, we observed that PODXL overexpressing countervailed NNT-AS1 depletion-mediated suppression on BC cell growth and Wnt pathway. 31782983 2020
CUI: C0002986
Disease: Fabry Disease
Fabry Disease 		0.010 AlteredExpression disease BEFREE Correlations were established between podocalyxin and podocin levels and clinical parameters associated with Fabry disease and preeclampsia. 30898510 2019
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.010 AlteredExpression disease BEFREE Association of serum podocalyxin levels with peripheral arterial disease in patients with type 2 diabetes. 31097305 2019
CUI: C0022650
Disease: Kidney Calculi
Kidney Calculi 		0.010 AlteredExpression disease BEFREE Evaluation of the urinary podocalyxin and nephrin excretion levels to determine a safe time interval between two sessions of SWL for renal stones: a non randomized exploratory study. 31321677 2019
CUI: C0025286
Disease: Meningioma
Meningioma 		0.010 AlteredExpression disease BEFREE The type I transmembrane protein podocalyxin like (PODXL) was markedly upregulated in DCC low expression meningiomas in six studies. 31083655 2019
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease 		0.010 GeneticVariation disease BEFREE Mutations in the podocalyxin-like gene (PODXL) have been recently identified in a consanguineous Indian family with juvenile-onset Parkinson's disease (PD) and 3 unrelated patients with PD. 31564376 2019
CUI: C0036221
Disease: Mast-Cell Sarcoma
Mast-Cell Sarcoma 		0.010 AlteredExpression disease BEFREE Subjects with D-PAD and medial calcific sclerosis (MCS) had significantly higher s-Podxl levels compared to the same group but without MCS (P < 0.02). 31097305 2019
CUI: C0085096
Disease: Peripheral Vascular Diseases
Peripheral Vascular Diseases 		0.010 AlteredExpression group BEFREE Association of serum podocalyxin levels with peripheral arterial disease in patients with type 2 diabetes. 31097305 2019
CUI: C0085413
Disease: Polycystic Kidney, Autosomal Dominant
Polycystic Kidney, Autosomal Dominant 		0.010 AlteredExpression disease BEFREE The levels of podocin and podocalyxin were higher in ADPKD patients with eGFR <60 mL/min/1.73 m2 than in ADPKD patients with eGFR ≥60 mL/min/1.73 m2. 31117091 2019
CUI: C0086445
Disease: Idiopathic Membranous Glomerulonephritis
Idiopathic Membranous Glomerulonephritis 		0.010 Biomarker disease BEFREE <b>Conclusion:</b> The combination of miR-193a, WT1, and PODXL might serve as a favorable strategy for expecting IMN prognosis. 31352863 2019
CUI: C0392525
Disease: Nephrolithiasis
Nephrolithiasis 		0.010 AlteredExpression disease BEFREE Evaluation of the urinary podocalyxin and nephrin excretion levels to determine a safe time interval between two sessions of SWL for renal stones: a non randomized exploratory study. 31321677 2019
CUI: C0494165
Disease: Secondary malignant neoplasm of liver
Secondary malignant neoplasm of liver 		0.010 Biomarker disease BEFREE Depletion of podocalyxin in a hemispleen mouse model of pancreatic cancer diminished liver metastasis without altering primary tumor size. 30975647 2019
CUI: C0887866
Disease: Monckeberg Medial Calcific Sclerosis
Monckeberg Medial Calcific Sclerosis 		0.010 AlteredExpression disease BEFREE Subjects with D-PAD and medial calcific sclerosis (MCS) had significantly higher s-Podxl levels compared to the same group but without MCS (P < 0.02). 31097305 2019
CUI: C1565489
Disease: Renal Insufficiency
Renal Insufficiency 		0.010 GeneticVariation disease BEFREE This is the first study to date that demonstrates, mechanistically, how autosomal dominant mutations in podocalyxin can lead to FSGS and renal insufficiency. 30737302 2019
CUI: C1704436
Disease: Peripheral Arterial Diseases
Peripheral Arterial Diseases 		0.010 Biomarker group BEFREE Multivariate regression showed that an increase of one standard deviation in s-Podxl was associated with an odds ratio of 3.4 (95% confidence interval = 2.2-4.6, P < 0.001) for the prevalence of PAD. 31097305 2019
CUI: C1839735
Disease: MILES-CARPENTER X-LINKED MENTAL RETARDATION SYNDROME
MILES-CARPENTER X-LINKED MENTAL RETARDATION SYNDROME 		0.010 AlteredExpression disease BEFREE Subjects with D-PAD and medial calcific sclerosis (MCS) had significantly higher s-Podxl levels compared to the same group but without MCS (P < 0.02). 31097305 2019
CUI: C2919166
Disease: Autosomal dominant focal segmental glomerulosclerosis
Autosomal dominant focal segmental glomerulosclerosis 		0.010 GeneticVariation disease BEFREE Recently, a novel heterozygous missense mutation c.T1421G (p. L474R) in the <i>PODXL</i> gene encoding podocalyxin was identified in an autosomal dominant focal segmental glomerulosclerosis (AD-FSGS) pedigree. 30523047 2019
CUI: C4275179
Disease: Young onset Parkinson disease
Young onset Parkinson disease 		0.010 GeneticVariation disease BEFREE Genetic analysis of PODXL gene in patients with familial and young-onset Parkinson's disease in a Taiwanese population. 31564376 2019
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.010 Biomarker disease BEFREE Serum podocalyxin levels correlate with carotid intima media thickness, implicating its role as a novel biomarker for atherosclerosis. 29321582 2018
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis 		0.010 Biomarker disease BEFREE Serum podocalyxin levels correlate with carotid intima media thickness, implicating its role as a novel biomarker for atherosclerosis. 29321582 2018
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases 		0.010 Biomarker group BEFREE In conclusion, s-Podxl is independently associated with carotid IMT and might be used as a novel biomarker for cardiovascular disease. 29321582 2018
CUI: C0011847
Disease: Diabetes
Diabetes 		0.010 AlteredExpression disease BEFREE Multiple logistic regression analysis showed that s-Podxl levels remained significantly associated with carotid IMT > 1 mm (OR: 1.15; 95% CI 1.02-1.31, p = 0.026) after adjustments for traditional cardiovascular risk factors such as age, sex, current smoking status, hypertension, dyslipidemias, and diabetes. 29321582 2018